Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Barbie

Showing results (101-110 of 120) with videos related to

Pageof 12
Sort By:
Cancer Research|February 3, 2016
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor MicroenvironmentShohei Koyama, Esra A Akbay, Yvonne Y Li, et al.
Cancer Cell|July 4, 2009
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancerKrishna M Vasudevan, David A Barbie, Michael A Davies, et al.
Nature|October 23, 2009
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1David A Barbie, Pablo Tamayo, Jesse S Boehm, et al.
Nature Biotechnology|April 19, 2016
Characterizing genomic alterations in cancer by complementary functional associationsJong Wook Kim, Olga B Botvinnik, Omar Abudayyeh, et al.
Cancer Immunology Research|September 8, 2025
Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid TumorsElliott J Brea, Simon Baldacci, Neil Savage, et al.
Cell Systems|August 25, 2017
Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular StatesJong Wook Kim, Omar O Abudayyeh, Huwate Yeerna, et al.
Cancer Discovery|August 5, 2025
Eradicating Drug Tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T cellular therapySimon Baldacci, Elliott J Brea, Francesco Facchinetti, et al.
Nature Genetics|May 11, 2021
Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependenceZhong Wu, Jin Zhou, Xiaoyang Zhang, et al.
Science Translational Medicine|September 13, 2021
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of <i>EGFR</i>-mutant lung cancerPınar Özden Eser, Raymond M Paranal, Jieun Son, et al.
Cell|November 3, 2018
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in MelanomaMoshe Sade-Feldman, Keren Yizhak, Stacey L Bjorgaard, et al.
Pageof 12

Showing results (101-110 of 120) with videos related to

Sort By:
Pageof 12
Cancer Research|February 3, 2016
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor MicroenvironmentShohei Koyama, Esra A Akbay, Yvonne Y Li, et al.
Cancer Cell|July 4, 2009
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancerKrishna M Vasudevan, David A Barbie, Michael A Davies, et al.
Nature|October 23, 2009
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1David A Barbie, Pablo Tamayo, Jesse S Boehm, et al.
Nature Biotechnology|April 19, 2016
Characterizing genomic alterations in cancer by complementary functional associationsJong Wook Kim, Olga B Botvinnik, Omar Abudayyeh, et al.
Cancer Immunology Research|September 8, 2025
Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid TumorsElliott J Brea, Simon Baldacci, Neil Savage, et al.
Cell Systems|August 25, 2017
Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular StatesJong Wook Kim, Omar O Abudayyeh, Huwate Yeerna, et al.
Cancer Discovery|August 5, 2025
Eradicating Drug Tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T cellular therapySimon Baldacci, Elliott J Brea, Francesco Facchinetti, et al.
Nature Genetics|May 11, 2021
Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependenceZhong Wu, Jin Zhou, Xiaoyang Zhang, et al.
Science Translational Medicine|September 13, 2021
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of <i>EGFR</i>-mutant lung cancerPınar Özden Eser, Raymond M Paranal, Jieun Son, et al.
Cell|November 3, 2018
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in MelanomaMoshe Sade-Feldman, Keren Yizhak, Stacey L Bjorgaard, et al.
Pageof 12